Status:
TERMINATED
Bosentan for Treatment of Hepatopulmonary Syndrome in Patients With Liver Cirrhosis
Lead Sponsor:
Medical University of Vienna
Conditions:
Hepatopulmonary Syndrome
Liver Cirrhosis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The most common observed cause of gas exchange abnormalities and hypoxemia in cirrhosis is the hepatopulmonary syndrome (HPS) with a reported prevalence of 20-47% in patients with hepatic impairment a...
Eligibility Criteria
Inclusion
- Presence of HPS
- Age ≥ 18 years
Exclusion
- Intracardiac shunting
- Pregnancy
- Known hypersensitivity to bosentan
- Use of glyburide
- Use of cyclosporin A
- Elevation of aminotransferase level of \> 3 times the upper limit of normal
- Use of rifampicin
- Females of childbearing potential without use of adequate contraception
- Systolic blood pressure \< 85 mmHg
- Clinical relevant anemia
- HIV-infection
Key Trial Info
Start Date :
October 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT01518595
Start Date
October 1 2011
Last Update
September 28 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University Vienna, Dpt. of Internal Medicine 3, Div. of Gastroenterology and Hepatology
Vienna, Austria, 1090